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Suomenkielinen yhteenveto  
Maavierailun tarkoitus  
Euroopan tautien ehkäisy- ja torjuntakeskus ECDC vierailee jäsenmaissa niiden hallitusten kutsusta 
keskustelemassa mikrobilääkeresistenssin ja hoitoon liittyvien infektioiden tilanteesta ja kansallisista 
ehkäisy- ja torjuntatoimista. ECDC hyödyntää indikaattori- ja kysymysluetteloa, joka perustuu pitkälti 
mikrobilääkkeiden maltillista käyttöä ihmislääketieteessä koskevan Neuvoston suosituksen (2002/77/EY) 
avainkohtiin sekä Neuvoston suositukseen potilasturvallisuudesta ja hoitoon liittyvien infektioiden 
ehkäisemisestä ja torjunnasta (2009/C 151/01). Suomen sosiaali- ja terveysministeriö kutsui ECDC:n ja 
Euroopan elintarviketurvallisuusviranomaisen (EFSA) yhteisvierailulle keskustelemaan 
mikrobilääkeresistenssistä ja hoitoon liittyvistä infektioista ihmisten ja eläinten hoidossa.  
Johtopäätökset  
Mikrobilääkeresistenssiä ja hoitoon liittyviä infektioita koskeva lainsäädäntö: tartuntatautilaki (583/1986), 
tartuntatautiasetus (786/1986), terveydenhuoltolaki (30.12.2010/1326) ja asetus laadunhallinnasta ja 
potilasturvallisuuden täytäntöönpanosta laadittavasta suunnitelmasta (341/2011). Nykyisessä laissa ei 
kuitenkaan ole erikseen määrätty mikrobilääkeresistenssiä ja hoitoon liittyvien infektioiden ehkäisemistä 
koskevasta kansallisesta strategiasta. Tartuntatautilaki ja -asetus ovat parhaillaan käsiteltävinä, ja 
terveydenhuoltorakenteen uudistus on vielä kesken. Uusi lainsäädäntö tulee sisältämään 
mikrobilääkeresistenssiä ja hoitoon liittyviä infektioita koskevia määräyksiä.  
Kansallinen mikrobilääkeresistenssin torjumiseen keskittynyt monisektorinen asiantuntijaryhmä on osa 
alojen välistä mekanismia (Intersectoral Coordination Mechanism, ICM), jonka toimintakausi jatkuu vuoteen 
2015 saakka. Asiantuntijaryhmän rooli on siinä mielessä epäselvä, ettei sillä ole selkää mandaattia eikä 
velvollisuuksia eikä se ole laatinut strategiaa, jolla vastataan mikrobilääkeresistenssin kasvuun. Ryhmälle ei 
ole määritetty budjettia eikä vielä ole selvää, käsitteleekö sama ryhmä myös hoitoon liittyviä infektioita vai 
perustetaanko sitä varten toinen asiantuntijaryhmä.  
Mikrobilääkeresistenssin ja hoitoon liittyvien infektioiden torjunnasta vastaa THL:n Tartuntatautiseurannan 
ja -torjunnan osasto (TATO) ja erityisesti Suomen tartuntatautirekisteri, johon tiedot tärkeimmistä taudeista 
ja mikrobikannat kootaan keskitetysti, yhteistyöhön perustuva mikrobilääkeresistenssin tutkimusryhmä FiRe 
(Finnish Study Group for Antimicrobial Resistance) ja Sairaalainfektio-ohjelma SIRO, joka seuraa ja torjuu 
hoitoon liittyviä infektioita. Hoitoon liittyvien infektioiden seuranta ei ole kaikissa sairaaloissa pakollista, 
vaan perustuu vapaaehtoisuuteen. SIRO-ohjelmaan osallistuu suuri osa Suomen sairaaloista, mutta eivät 
kaikki. Suomessa on toteutettu prevalenssitutkimuksia, joista viimeisin julkaistiin vuonna 2005. Vuonna 2011 
Suomessa tehtiin prevalenssitutkimus, joka oli osa ECDC:n toteuttamaa prevalenssitutkimusta hoitoon 
liittyvistä infektioista ja antibioottien käytöstä eurooppalaisissa ensiavuissa ja päivystyssairaaloissa.  
Infektioiden torjunta  
Suomessa infektioiden torjunta on kirjattu lakiin vain joiltain osin. Infektioiden torjuntaa, 
mikrobilääkeresistenssiä ja hoitoon liittyviä infektioita koskeva lainsäädäntö puuttuu eikä asiaa koskevaa 
valtakunnallista toimintasuunnitelmaa tai strategiaa ole. Hoitoon liittyvien infektioiden seuranta ja torjunta 
on sairaanhoitopiirien vastuulla, eikä lainsäädäntö määrää sairaaloita laatimaan ja toimeenpanemaan 
infektioiden torjuntaan tähtääviä rakenteita ja prosesseja. Tämän seurauksena sairaanhoitopiireissä ja eri 
kunnissa on päädytty noudattamaan erilaisia käytäntöjä. Valtakunnallisesti ei ole tunnistettavissa mitään 
tahoa, jonka vastuulla olisi reagoida resistenssin lisääntymiseen ja infektioepidemioiden esiintymiseen sekä 
valvoa ja torjua mikrobilääkeresistenssiä ja hoitoon liittyviä infektioita Suomessa.  
Mikrobilääkeresistenssi  
Suomessa monilääkeresistenttien mikrobien määrä on vähäinen, mutta määrä kasvaa hitaasti. Eri 
terveydenhuollonlaitosten välillä leviävät resistentit kannat ovat kasvava ongelma. Vuonna 2010 MRSA- 
prevalenssi on keskimäärin 3 %, mutta joillakin alueilla osuus on suurempi, mikä osoittaa näiden toimivan 
alkulähteenä bakteerien leviämiselle ympäristöön. Laajakirjoisia beetalaktamaasientsyymejä (ESBL) 
tuottavien enterobakteerienen määrä on Suomessa kasvanut eksponentiaalisesti ja kaksinkertaistunut jo yli 
4 prosenttiin. Myös useille tai kaikille saatavissa oleville antibiooteille resistenttejä bakteereja (esimerkiksi 
karbapenemaasia tuottavat enterobakteerit, CPE) on tavattu ja niiden esiintyvyys kasvaa hitaasti. Tämä 
esiintyvyyden lisääntymisen torjunta sairaalaepidemioista endeemiseen tilanteeseen saakkaon jäänyt 
paikalliselle tasolle ja lähinnä sairaaloiden omalle vastuulle, eikä infektiotorjunta ole ollut systemaattista 
koko maassa.  
Antibioottien käytön valvonta  
Suomessa antibioottien käyttöä valvoo kaksi tahoa: Lääkealan turvallisuus- ja kehittämiskeskus Fimea ja 
Kela. Tietojen raportoiminen ja lääkemääräysten indikaatioiden kerääminen ei kuitenkaan ole pakollista. 
Tietoja antibioottien käytöstä käyttöaiheen perusteella ei ole saatavissa eikä laskelmia antibioottien 
kulutuksesta avoterveydenhuollossa ja sairaalahoidossa pystytä tekemään.  
Suositukset  
 Infektioiden torjuntaa koskevaa lainsäädäntöä pitäisi tarkistaa, esimerkiksi vertaamalla sitä muiden 
Euroopan maiden vastaavaan lainsäädäntöön. Joissain maissa, kuten Isossa-Britanniassa ja 
Ranskassa, mikrobilääkeresistenssiä ja hoitoon liittyviä infektioita koskevien lakien säätäminen on 
saanut valvovat viranomaiset ja terveydenhuollon tahot toteuttamaan ja seuraamaan 
valtakunnallisia strategioita.  
 Lainsäädäntö voisi sisältää selkeän mandaatin ja budjetin alojen väliselle mekanismille (ICM), 
mikrobilääkeresistenssiä ja hoitoon liittyviä infektioita koskevien valtakunnallisten strategioiden ja 
toimintasuunnitelmien laatimiselle ja toimeenpanemiselle sekä valvovan tahon määrittämiselle ja 
strategioiden toimeenpanon valvonnassa käytettäville rakenteille ja prosesseille.  
 Mikrobilääkeresistenssin ja hoitoon liittyvien infektioiden torjuntaa ja valvontaa on ehdottomasti 
vahvistettava Suomen sairaaloissa ja muissa terveydenhuoltolaitoksissa. Kasvun hillitsemiseen on 
osallistuttava laajasti sekä paikallisella että valtakunnallisella tasolla.  
 Keskeisellä sijalla on laatia ja toimeenpanna valtakunnallinen toimintasuunnitelma, valtakunnalliset 
ja paikalliset mikrobilääkeresistenssin torjuntaohjeet, mikrobilääkkeiden maltillinen käyttö ja 
hoitoon liittyvien infektioiden torjuminen.  
 Vastuu mikrobilääkeresistenssin ja hoitoon liittyvien infektioiden torjunnasta tulee määrätä 
valtakunnalliselle taholle, joka myös koordinoi ja valvoo toimintaa sekä kantaa niistä vastuun. Myös 
laillinen toimintavalta ja vastuu tulee määrätä tälle samalle taholle.  
 Asianomaisen viranomaisen on seurattava myös indikaattoreita, jotka valvovat 
mikrobilääkeresistenssiä ja hoitoon liittyviä infektioita koskevien strategioiden toimeenpanoa. 
Mikrobilääkeresistenssiä ja hoitoon liittyviä infektioita koskevaa viestintää ja yhteistyötä kaikkien 
asianosaisten väillä tulee kehittää.  
 Alojen välisen yhteistyön (ICM) valtuuksia on laajennettava. Lisäksi sillä tulee olla vahva poliittinen 
tuki, selkeä mandaatti ja määritelty budjetti.  
 Osana ICM:n mandaattia voisi olla mikrobilääkeresistenssin ja hoitoon liittyvien infektioiden 
torjuntaa koskevien valtakunnallisten strategioiden ja toimintasuunnitelmien kehittäminen sekä 
niiden toimeenpanon valvominen. ICM voisi lisäksi arvioida resistenssin vaikutuksia terveyteen ja 
talouteen.  
 Myös infektioiden torjuntaan ja seurantaan, sekä infektiosairauksiin erikoistuneiden lääkäreiden ja 
muiden ammattilaisten roolia tulisi vahvistaa sairaaloissa ja heidän osallistumistaan hoitoon 
liittyvien infektioiden diagnosointiin ja tietojen keräämiseen tulisi lisätä.  
 Sairaaloissa hoitoon liittyvien infektioiden seurantaa tulisi tehostaa ja tiedot välittää viipymättä 
infektioiden torjuntaan ja seurantaan sekä infektiosairauksiin erikoistuneille lääkäreille ja muille 
ammattilaisille, jotta he voisivat seurata hoitoon liittyvien infektioiden määrää sairaalassa ja puuttua 
tarvittaessa tilanteeseen.  
 Tiedot hoitoon liittyvistä infektioista olisi syytä kerätä systemaattisesti ja ilman turhia viiveitä 
nykyistä useammasta sairaalasta ja tiedot raportoitava SIROlle, joka kokoaa ajantasaiset tiedot ja 
kattavat epidemiologiset tiedot.  
 Mikrobilääkkeiden käyttöä voisi tilastoida indikaatioiden perusteella hyödyntämällä Kelan tietoja 
paremmin. Vastaavien tietojen keräämistä FIMEAsta olisi myös syytä harkita.  
 Mikrobilääkkeiden maltillista käyttöä olisi tuettava perustamalla sairaaloihin poikkitieteellisiä 
mikrobilääkevalvontaryhmiä, jotka seuraisivat mikrobilääkkeiden käyttöä infektiolääkärin johdolla.  
 Mikrobilääkkeidenkäyttöä koskeva palaute voitaisiin välittää lääkäreille sairaaloissa ja 
avoterveydenhuollossa, jotta lääkkeiden määräyskäytäntöjä saadaan kohennettua.  
 Ihmisten ja eläinten terveydestä ehdotetaan laadittavaksi vuosittain yhteinen, 
mikrobilääkeresistenssin esiintyvyyttä koskeva raportti. Eurooppalaiselle mikrobilääkeresistenssin 
valvontaverkostolle (EARS-Net) ehdotetaan raportoitavan vuosittain. Tähän määritetään tarvittavat 
resurssit.  
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Executive Summary 
 
Rationale and purpose of the country visit 
The European Centre for Disease Prevention and Control (ECDC) performs country visits upon 
invitation from the respective governments to discuss the status and national infrastructure 
for the prevention and control of antimicrobial resistance (AMR) and healthcare-associated 
infections (HAIs). ECDC uses a list of indicators and questions which are primarily based on 
key statements from the Council Recommendation on the prudent use of antimicrobial agents 
in human medicine (2002/77/EC), as well as the Council Recommendation on Patient Safety, 
including the Prevention and Control of Healthcare -Associated Infections (2009/C 151/01). 
An invitation from the Finnish Ministry of Social Affairs and Health was sent requesting a joint 
visit from ECDC and the European Food Safety Authority (EFSA) to discuss issues related to 
AMR and healthcare-associated infections (HAI) in both human and veterinary settings.  
Conclusions 
Legislation for AMR and HAIs falls under the Communicable diseases Act 504/1986, the 
Communicable Diseases Decree 786/1986, the Health Care Act 30.12.2010/1326, the Health 
Care Decree 341/20. At present this Act, however, does not include a section for a national 
strategy for the prevention of AMR and HAIs. The Communicable Disease Act and Decree are 
undergoing revision and a reorganisation of the healthcare structure is in progress. Specific 
legislation for AMR and HAI will be included in the new legislation.  
The current National Advisory Committee on Antimicrobial Resistance Prevention is a multi-
sectoral committee that has the role of Intersectoral Coordination Mechanism (ICM) and has 
a life expectancy until 2015. This committee does not appear to have a well-delineated role, 
as it has no clear mandate, responsibilities and has not yet outlined a strategy to address the 
rise in AMR. Furthermore, it has no dedicated budget and it is not yet known whether this 
committee or whether a separate committee will be formed will also address HAI. 
Surveillance of AMR and HAIs is performed by the Department of Infectious Disease 
Surveillance and Control (TATO) and more specifically by the National Infectious Disease 
Register (NIDR), the register for notifiable diseases and microbial strain collection, the 
collaborative network on Antimicrobial Resistance Surveillance (FiRe), the Healthcare-
Associated Infections Programme (SIRO) which performs national HAI surveillance. 
Surveillance for HAIs in all hospitals is not mandatory, but rather voluntary. Although SIRO 
involves a large number of hospitals, not all hospitals in the country currently participate. 
Finnish point prevalence surveys (PPSs) have been performed, the last one published in 
2005. In 2011, Finland performed a PPS, thus participating in the ECDC PPS of HAIs and 
antimicrobial use in European acute care hospitals. 
 
 
 
 
ECDC country visit to discuss AMR issues COUNTRY VISIT REPORT 
 
 
 
6 
 
 
 
 
 Infection control 
Infection control in Finland is currently included only in some parts of the legislation, but 
there are no specific laws for infection control and the prevention of AMR or HAIs, nor is 
there a national action plan or strategy. Control of HAIs is under the responsibility of the 
hospital districts and there are no mandatory legal requirements for infection control 
structures and processes in hospitals. This has led to the development and practice of 
different approaches within and between health districts and municipalities. At a national 
level, there appears to be no coordinating body that has full responsibility of addressing this 
rise in resistance, outbreaks and the monitoring of AMR and HAIs in Finland as a whole.  
Antimicrobial resistance 
Rates of multidrug-resistant bacteria in Finland are low, but are slowly rising. There is clear 
interchange and spread of resistant bacteria between healthcare settings and has been 
identified as a rising problem. Data for MRSA from 2010 show 3% prevalence, with some 
areas reporting higher percentages, clearly representing reservoirs for spread to surrounding 
areas. The percentage of extended-spectrum beta-lactamase (ESBL)-producing 
Enterobacteriaceae has increased in an exponential fashion in Finland, doubling to over 4%. 
Bacteria that are resistant to almost all or all-available antibiotics, e.g. carbapenemase-
producing Enterobacteriaceae (CPE) have been reported and their incidence is slowly rising. 
Management of this increase, starting from hospital outbreaks and leading to establishment 
of endemicity, has been addressed mostly at the local, hospital level and infection control 
measures are not homogeneously implemented across the country.  
 
Antibiotic use and monitoring 
Two institutions monitor antibiotic use in Finland: the Finnish Medicines Agency (FIMEA) and 
the Social Insurance Institution of Finland (KELA). Data reporting and collection on 
indications for the prescription are not, however, mandatory and no data can be obtained 
about antibiotic use by indication, nor can calculations be made for the consumption of 
antibiotics in outpatient or inpatient care. 
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Recommendations 
 There is a need for an overview of the current legislation on infection control, which 
could be compared to similar legislations in other European countries. In some 
countries in Europe, examples of which are the United Kingdom and France, the 
creation of a legal infrastructure has been able to empower monitoring bodies and 
healthcare structures to implementation and monitor national strategies for AMR and 
HAIs. 
 Included in this legislation could be a clear mandate and budget for the ICM, the 
creation and implementation of national strategies and action plans for AMR and 
HAIs, having a specific responsible body for the oversight and using structure and 
process indicators to monitor the implementation of the strategies. 
 It is essential that prevention and control of AMR and HAIs in Finnish hospitals, in 
other healthcare facilities and the community be strengthened. Efforts to control this 
rise must involve all stakeholders at all levels, national and local.  
 It would be important to develop and implement a national action plan, national and 
local guidelines for AMR, prudent use of antibiotics and the prevention of HAIs.  
 Responsibility for combating AMR and HAIs in Finland should be clearly assigned to a 
national overseeing body that will coordinate, monitor and have the overall 
responsibility for this. Legal authority and responsibility should be assigned to this 
body and be exercised. 
 This overseeing body should also follow indicators that monitor the implementation of 
the strategies for AMR and HAIs. Communication between all relevant parties and 
collaboration should be enhanced with regard to the overall status of AMR and HAIs in 
Finland. 
 There is a need to empower the current ICM. It should have strong political 
endorsement and support and should be given a clear mandate and dedicated 
budget. 
 The ICM could, as part of its mandate, develop national strategies and action plans 
for the control AMR and HAIs and monitor their implementation. The ICM could also 
evaluate the impact of resistance on health and economic outcomes. 
 It is important to strengthen the role of infection prevention and control practitioners 
(ICPs) and infectious disease (ID) physicians in hospitals, and their involvement in 
diagnosing and collecting data on HAIs. 
 Active surveillance of HAIs in hospitals should be enhanced and data fed back in a 
timely manner to ICPs and ID physicians in hospitals to be able to monitor their HAI 
rates and make appropriate interventions. 
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 Data on HAI could be collected in a systematic and timely fashion and from more 
hospitals and reported to SIRO, allowing for timely information and more complete 
epidemiological data. 
 Measurement of antibiotic use in the community according to indication could be 
obtained by optimal use of indication data from KELA. Ways to also obtain such data 
from FIMEA could be considered.  
 Prudent use of antibiotics should be strengthened by formation of multidisciplinary 
antibiotic monitoring teams in hospitals led by ID physicians.  
 Feedback of data on antibiotic use could be fed back to physicians at the hospital level 
and the community level for improvement of prescribing practices. 
 An annual, joint human and veterinary report on prevalence of AMR from humans and 
animals is suggested. Annual reporting to EARS-Net is suggested and necessary 
resources should be allocated for this purpose. 
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1 Background  
1.1 Rationale for country visits to discuss 
antimicrobial resistance (AMR) issues 
After the introduction of antibiotics in the 1940s, it soon became clear that antibiotic usage 
promotes the rise of antibiotic-resistant bacterial strains in bacteria such Staphylococcus 
aureus and Mycobacterium tuberculosis (TB). During the following decades, the increasing 
number of antibiotic-resistant strains could still be treated because of the availability of new 
antibiotics giving the possibility of therapeutic options for patients infected with resistant 
bacteria. In the 1990s, however, the development of new antibiotics began to and continued 
to markedly decrease following a simultaneous rise in the emergence of bacteria resistant to 
multiple antibiotics, resulting in limited availability for agents for the treatment of patients. 
Today, bacteria that are totally (or almost totally) resistant to antibiotics, many with new 
resistance mechanisms, are emerging and spreading in Europe and worldwide. The 
emergence and spread of bacteria that are resistant to antimicrobials is a threat to patient 
safety and is associated with higher morbidity and mortality in infected patients 
 
In 1998, the Chief Medical Officers of the European Union (EU) Member States (MS) 
recognized this evolving problem and took the initiative to the first major conference on AMR 
in Copenhagen, Denmark, which resulted in the Copenhagen Recommendations (Report 
from the Invitational EU Conference on the Microbial Threat, Copenhagen, 
Denmark, 9 -10 September 1998). 
 
In November 2001, the EU Health Ministers (Council) adopted a Council Recommendation 
on the prudent use of antimicrobial agents in human medicine (2002/77/EC), 
which covers most topics of importance for prevention and control of AMR including the 
development of an Intersectoral Coordination Mechanism (ICM). 
 
In 2005, the European Commission reported to the Council on this progress in Member States 
in the Report from the Commission to the Council on the basis of Member States 
reports on the implementation of the Council recommendation (2002/77/EC) on 
the Prudent Use of Antimicrobial Agents in Human Medicine (COM (2005) 0684). 
In this report, it is stated that: “The ECDC should be able to assist the Commission in the 
future preparation of implementation reports and of recommendation proposals.” 
 
In June 2009, the EU Health Ministers adopted a Council Recommendation on Patient 
Safety, including the Prevention and Control of Healthcare -Associated Infections 
(2009/C 151/01), which discusses the importance of combating both AMR and HAI, issues 
that are key to patient safety. 
 
The European Centre for Disease Prevention and Control (ECDC) performs country visits upon 
invitation from the respective governments, to discuss the status and national infrastructure 
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for the prevention and control of antimicrobial resistance (AMR) and healthcare-associated 
infections (HAIs). ECDC has so far visited 16 countries: 14 European Union (EU) Member 
States, four of these more than once, and 2 EU enlargement countries.  
 
In order to systematically discuss all aspects of the policies, practices and infrastructure that 
involve AMR and HAI in countries, ECDC uses a list of indicators and questions which are 
primarily based on key statements from the Council Recommendation 2002/77/EC, as well as 
the Council Recommendation 2009/C 151/01. At the end of the visit an oral, preliminary 
report is presented to the country, containing observations and conclusions made during the 
visit and suggestions are proposed. The final report is subsequently prepared in collaboration 
with the key stakeholders in the country. 
 
During these visits ECDC meets with stakeholders involved in the monitoring, prevention and 
control of AMR, antibiotic use and HAIs exchange views and facts and ideas about the 
present situation and future goals of their country. These stakeholders are from all areas of 
public health, veterinary and human medicine, social security, national insurance, medicines 
agency as well as the Ministry of Health and any other involved party. 
 
An invitation from the Finnish Ministry of Social Affairs and Health was sent requesting a joint 
visit from ECDC and the European Food Safety Authority (EFSA) to discuss issues related to 
AMR and healthcare-associated infections (HAIs) in both human and veterinary settings, 
which took place from 29 October to 2nd November 2012.  
 
1.2 Purpose 
Council Recommendation of 15 November 2001 on the prudent use of 
antimicrobial agents in human medicine (2002/77/EC) outlines the threat that AMR 
poses to human health and advocates for a range of actions to be taken for its prevention 
and control. Council Conclusions on antimicrobial resistance (AMR) of 10 June 2008 
reiterated this call for action. 
 
To assist Member States, candidate and potential candidate countries in implementing the 
Council Recommendation, ECDC has developed a process for and is carrying out, upon 
invitation from national authorities, country visits to specifically discuss and assess the 
situation of the country regarding prevention and control of AMR through prudent use of 
antibiotics and infection control. These country visits also help document how Member States 
have approached this implementation and deployed national activities and support the 
European Commission in evaluating this implementation.  
 
The main output of the visit is a report from the ECDC Team provided to the inviting national 
authority. To help the ECDC Team ensure consistency of the visits and follow-up of progress 
of countries, an assessment tool has been developed. The assessment tool includes ten 
topics. These topics are regarded as core areas for successful prevention and control of AMR 
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and are based on Council Recommendation 2002/77/EC and on Council Conclusions of 10 
June 2008. The assessment tool is used as a guide for discussions during the visit. 
 
2 Overview of the situation in Finland 
2.1 Healthcare structures 
2.1.1 The Ministry of Social Affairs and Health (MSAH) 
The MSAH is responsible for all health care legislation and regulations and for the overall 
planning, management and monitoring of the fight against infectious diseases. Provisions for 
the control of infectious diseases can be found in the infectious diseases legislation, specified 
in regulations. The MSAH represents the legal and political body for the administration of the 
health care system and prevention of infectious diseases. There are currently two experts on 
infectious diseases working at MSAH and monitoring the status of infectious diseases in 
Finland. 
 
2.1.2 Legislation for AMR and HAI 
The provision of health care services is regulated by Health Care Act 30.12.2010/1326.  
The main legislation that refers to AMR and infection control (IC) are the Communicable 
diseases Act 504/1986, the Communicable Diseases Decree 786/1986, and the Health Care 
Act, as well as a number of amendments to these laws. The areas of AMR and HAIs that are 
included in the Communicable Diseases Act cover focus only on certain points, e.g. that 
Hospital Districts are in charge of HAIs (3§ etc.) and that THL can perform surveillance of 
infectious diseases and laboratory-based investigation and collect data on resistant to 
antimicrobial agents (23a§). At present this Act does not include a section on the 
development of a national strategy for the prevention of AMR and HAIs.  
In 2011 a Health Care Decree (341/2011) was passed for patient safety and quality 
assurance and in June 2011 a new governmental programme included four items that 
pertained to patient safety, although they did not refer directly to AMR and/or HAIs. The 
Communicable Disease Act and Decree are currently undergoing revision and a 
reorganisation of the healthcare structure is in progress. Specific legislation for AMR and HAIs 
will be enhanced and included in the new legislation. The new legislation and the structural 
changes may affect the involvement, responsibility and organisation of municipalities and all 
other stakeholders in this field. 
 
2.1.3 Municipalities 
In general, public health in Finland is the responsibility of the municipalities. The majority of 
Finnish health care services are organised and provided by the municipal health care system. 
Municipalities are legally required to organise adequate health services i.e. specialised care 
for their residents. There are currently 336 municipalities in Finland with a median size of less 
than 6,000 inhabitants. To fund these services, municipalities levy taxes and receive state 
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subsidies.  
 
2.1.4 Health centres 
Primary health care in Finland is provided through “health centres”. Smaller municipalities 
may merge their health centres into a joint “health centre”. Generally, the range of services 
provided by the health centres is very broad and includes a wide set of preventive and 
primary care, specialized care, rehabilitation, long-term-care (together with social services) 
and dental care services. In the absence of national minimum coverage standards, each 
municipality is free to determine its own scope of services it provides. Since the Finnish 
health care system is decentralized and national steering is rather weak and consequently, 
each municipality determines its own scope of coverage within general limits set by national 
legislation, a fair amount of variation exists geographically and outpatient service volumes for 
primary care visits, dental care, mental health care and elective surgery differ across 
municipalities. 
 
2.1.5 Hospitals 
Municipalities are organised into “hospital districts” There are 20 + 1 hospital districts, each 
of which is owned and funded by its member municipalities, which provide specialist care to 
the municipal system. Each hospital district has one or several hospitals, one of which is the 
central hospital. In addition, there are 5 University hospitals, which are tertiary hospitals in 
Finland and which provide care for the hospital districts. 
 
2.1.6 National Supervisory Authority for Welfare and Health (Valvira) 
Valvira is a nationwide authority which operates under the MSAH and which guides 
municipalities and Regional State Administrative Agencies (AVIs) on issues of legislation 
associated with Valvira’s jurisdiction. There are six regional agencies that started operating 
on 1st January 2010. These agencies tasks are those of the former state provincial offices e.g. 
occupational health, safety districts, environmental permit agencies and regional 
environmental centres. The agencies work in close collaboration with local authorities. 
In addition, Valvira supervises the implementation and compliance of various fields of 
healthcare and welfare with legal regulations. This is done by the AVIs fostering regional 
parity by executing all legislative implementation, steering and supervision of functions in the 
regions. The AVIs strengthen implementation of the public’s basic rights and legal protection, 
access to basic public services, environmental protection, environmental sustainability, public 
safety and a safe and healthy living and working environment in the regions. 
 
2.1.7 National Institute for Health and Welfare (THL) 
The National Public health Institute (KTL) and the National Research and Development 
Centre for Welfare and Health (STAKES) were merged in 2009 to create the THL. THL’s 
functions are defined by the following Decree: “to function as an expert authority in matters 
concerning social welfare, special care of persons with intellectual and developmental 
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disabilities, public health, specialised health care, mental health work, infectious diseases, 
environmental health, gene technology and other matters related to the Institute's sphere of 
activity. Its functions are not limited to the Health Care Act and Decree, but are also 
responsible for many other tasks that fall under the Communicable Disease Act and Decree. 
The main functions of THL are to promote the welfare and health of the population, prevent 
diseases and social problems and develop social and health services for Finland. It pursues 
and carries out its objectives by means of research, development activities and official tasks, 
steering through information as well as international co-operation. In its capacity as the 
statutory statistical authority for health and welfare, THL maintains and promotes the use of 
a strong knowledge base within the field. THL, however, has no legal authority.  
 
 
2.2 Monitoring of antimicrobial resistance (AMR) 
2.2.1 The Department of Infectious Disease Surveillance and Control 
(TATO) 
TATO is part of THL and has branches both in Helsinki and Turku. It contains both the 
epidemiological and microbiological expert functions for communicable disease surveillance, 
outbreak investigations and preparedness. The statutory basis of surveillance is by the 
Communicable law and Decree from 1986. 
The surveillance systems that belong to TATO are: the National Infectious Disease Register 
(NIDR), the register for notifiable diseases and microbial strain collection, the collaborative 
network on Antimicrobial Resistance Surveillance (FiRe), the Healthcare-Associated Infections 
Programme (SIRO)  
which performs national HAI surveillance and guidance and is a part of ”patient safety”. The 
mandate of the department also contains early outbreak recognition, investigation and 
control, and the syndromic surveillance in primary health care. 
For epidemiological and microbiological investigations, TATO jointly collaborates with the 
Finnish Food Safety Agency (EVIRA), especially in the case of food- and waterborne 
outbreaks. In contrast to TATO, EVIRA has a clear mandate and responsibility for intervening 
when there are outbreaks.  
2.2.2 National Infectious Disease Register (NIDR)  
Certain bacterial species that display specific AMR profiles belong to the statutory Infectious 
Disease Registry monitoring in Finland and are mandatorily reported to the NIDR which is 
located in Helsinki. The NIDR strain collection of antimicrobial-resistant bacteria, submitted 
systematically in accordance to the Communicable Disease Decree, is maintained by the 
Bacteriology Unit in Helsinki and the Antimicrobial Resistance Unit in Turku. The data sources 
are the clinical microbiology laboratories, most of which are located in the 20 central hospitals. 
These supply 97% of all laboratory notifications.  
The notification is performed electronically from the laboratory mainframe computers to the 
NIDR database within 3 working days of the results. The remaining 3% of notifications are 
made from the smaller laboratories using paper forms. Subsequently, reference laboratories 
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at THL submit species confirmation, susceptibility testing, sub-typing and other data of the 
submitted isolate, to the NIDR main database electronically. Some reference laboratories 
have this process completely integrated into their daily laboratory data processing activities. 
Some THL reference laboratories use a separate computer program to enter the isolate 
testing data, which are then uploaded into NIDR in batches. By 2013, all THL bacteriological 
reference laboratory functions will be using the same IT software for their daily work and also 
to send notifications to the main register.  
 
All data/cases in the NIDR have a unique national person identifier, which is common across 
the entire healthcare and numerous other administrative systems, including all national 
registers. This is used for linking data from different sources with cases with predefined 
computer algorithms.  
 
2.2.3 Feedback and accessibility of data 
Each hospital district and primary health care centre has the right to access all data in the 
NIDR that concern cases in their own area, including data produced by the reference 
laboratories. THL has instituted a process by which individuals who belong to the infectious 
disease control teams are nominated by the Hospital Districts and Primary Health Care 
Centres and have the right to access the NIDR. 
Feedback is provided by the NIDR to clinical microbiology laboratories every six months 
regarding detailed, isolate-specific data for each isolate that was submitted to THL. Weekly 
updates are performed at the NIDR public web service and the results are reported annually 
in the Communicable Disease Report. In addition to this, the THL reference laboratories also 
directly report back the results of their testing to the referring clinical microbiological 
laboratories. 
 
The following bacteria that display certain antimicrobial resistance profiles are reported to 
NIDR and in most cases also sent to reference laboratory at THL: 
 Enterobacter cloacae (strains with reduced susceptibility or resistance to 
carbapenems) 
 Enterococci (strains with reduced susceptibility to vancomycin - VRE)  
 Escherichia coli (strains with reduced susceptibility to third -generation 
cephalosporins) 
 Escherichia coli (strains with reduced susceptibility or resistance to carbapenems) 
 Klebsiella pneumoniae (strains with reduced susceptibility to third- generation 
cephalosporins) 
 Klebsiella pneumoniae (strains with reduced susceptibility or resistance to 
carbapenems) 
 Staphylococcus aureus (methicillin resistant Staphylococcus aureus -MRSA)  
 Staphylococci (vancomycin-resistant strains - VRSA)  
 Streptococcus pneumoniae (blood or CSF isolates with reduced susceptibility to 
penicillin) 
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2.2.4 The Finnish Study Group for Antimicrobial Resistance (FiRe) 
network and Finnish Study Group for Antimicrobial Resistance 
(FinRes) 
 
a. FiRe 
FiRe is a coalition of all 24 major clinical microbiology laboratories and is a voluntary co-
operation body. The Antimicrobial Resistance Unit of THL in Turku coordinates the FiRe 
network. Financing for meetings comes from the pharmaceutical industry, and for the data 
management development project, from the MSAH and THL. The FiRe laboratories receive no 
financial compensation for their work.  
FiRe's primary role is to provide reliable and comparable data on clinically important bacteria 
and the prevalence of antimicrobial resistance in Finland. The network monitors the 
antimicrobial susceptibility of the 15 most important clinical bacterial species annually.  
 
b. FinRes 
FinRes is a working group within FiRe that has been monitoring data on antimicrobial 
susceptibility since 1991. FinRes has been submitting data to the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) starting in 2010. Since 2011, all laboratories in 
Finland are using EUCAST breakpoints.  
The network includes all major Finnish clinical microbiology laboratories (24 laboratories in 
2012) and is geographically and at the population level, quite comprehensive. The network 
follows the antimicrobial susceptibility profiles of the 15 most important clinical bacterial 
species annually (one isolate/patient/specimen type/follow-up period). Annually FinRes 
monitors 400,000 bacterial isolates, and more than 3 million antimicrobial susceptibility 
results, i.e. approximately 95% of results from Finland. The last internal report by FiRe is 
from 2010. 
Unfortunately, a printed FinRes report has not been published since 1999. A printed report 
covering the years 1997-2010 is in press and will be published on the FinRes website in 
November 2012 (www.finres.fi). 
 
 
2.3 Monitoring of healthcare-associated infections 
(HAIs) 
2.3.1 General 
In Finland, surveillance for HAIs in all hospitals is not mandatory, but rather voluntary. 
Hospitals can voluntarily participate and report to the Healthcare-Associated Infections 
Programme (SIRO). Participating hospitals can submit uniform surveillance data only for 
certain surgical site infections and for bloodstream infections using standardised HAI case 
definitions. Although SIRO involves a large number of hospitals, not all hospitals in the 
 
 
 
 
ECDC country visit to discuss AMR issues COUNTRY VISIT REPORT 
 
 
 
16 
 
 
 
 
country currently participate. For hospitals that do not participate in SIRO, case definitions 
and data reporting are not uniform and reporting to a national body is not performed.  
Finnish point prevalence surveys (PPSs) have been performed in the past, the last one 
published in 2005. Most recently, in 2011, Finland performed a PPS, participating in the ECDC 
PPS during which all hospitals involved used uniform case definitions.  
Note: The Finnish results of the ECDC PPS were published in January 2013 in the Finnish 
Medical Journal.  
 
2.3.2 Healthcare-Associated Infections Programme (SIRO)  
SIRO is a surveillance network, which is coordinated by the Epidemiologic Surveillance and 
Response Unit of THL in Helsinki. It collects standardised data on HAIs as well as 
antimicrobial susceptibility data from an expanding number of Finnish hospitals since 1999. 
There are currently 15 voluntarily participating hospitals in Finland, which cover the majority 
of hospital beds nationally.  
 
The last available data that were published by SIRO are from 1999–2006. The conclusions 
from these data were that “the rate of nosocomial bloodstream infections (BSIs) in Finland is 
similar to the rates in other European countries and the United States. BSIs caused by MRSA, 
VRE and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are still 
rare, but their proportion has nearly doubled compared with the past”. The last available 
published data from SIRO for surgical site infections in orthopaedics specifically, were from 
1999–2005. The conclusions from those reports were that: “The SSI rates in Finland are 
clearly higher than the rates reported by the United States and somewhat higher than the 
rates in the Netherlands, England and Germany. The higher rates are partly explained by 
post-discharge surveillance, but even during in-hospital surveillance, the interpretation of the 
definition of SSI as well as the diagnostic practices may vary.” 
 
At the SIRO website there is a list of publications on different HAIs including a comprehensive 
estimate of disease burden from HAIs in Finland, but no recent data since 2006, annual data 
or timely data are available at present. 
 
2.3.3 Outbreak investigations and reporting 
There is no mandatory notification for HAI outbreaks in hospitals. Healthcare-associated 
outbreaks are the responsibility of the hospital itself. Small outbreaks in one municipality are 
the responsibility of the municipal authorities. Outbreaks that occur in more than one 
municipality as well as large outbreaks are dealt with by regional and national authorities, 
such as THL and EVIRA and national authorities manage international outbreaks 
Because of lack of mandatory notification for HAI outbreaks, information, communication and 
action about the outbreak depend solely on individual initiative. Microbiology laboratories or 
infectious disease team members who become aware of an increasing incidence in infections 
can voluntarily inform relevant parties at a hospital or a higher level. Following this, however, 
there is no formal or mandatory involvement and any advice or intervention is entirely 
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voluntary. This may be in the form of informal advice, but there is no mechanism to ensure 
notification, involvement or follow- up.  
In contrast to HAI outbreaks, for food- and waterborne outbreaks, there is mandatory 
notification and Evira is directly responsible and has a representative present in the 
municipality with risk management authority. 
 
2.4 Infection control 
2.4.1 General  
Infection control in Finland is currently included in only a few sections of the legislation. 
There are no specific laws, however, pertaining to the infection control and prevention of 
AMR or HAIs, nor have national action plans or strategies been developed. Comprehensive 
national guidelines are available for the control of certain alert organisms, namely MRSA, VRE 
and C. difficile for acute care hospitals and long-term care facilities (LCTFs) are published on 
the THL website (and are now being updated). For other resistant organisms, such as ESBL-
producing Enterobacteriaceae and carbapenemase-producing Enterobacteriaceae (CPE), 
guidelines are available mostly for laboratory diagnoses and screening, but no comprehensive 
guidelines for the prevention of HAIs is available.  
The control of HAIs is under the responsibility of the hospital districts. Hospitals create, adopt 
or adapt available international guidelines and/or recommendations from the Finnish 
Infection Control Society manual, which is distributed to and extensively used in healthcare 
settings across the country. This has led to the development and practice of different 
approaches within and between hospitals, health districts and municipalities.  
2.4.2 Infection control training  
The Finnish Society for Infection Control performs training of healthcare workers. Since 1984 
a one-year, part-time course for nurses has been available, leading to infection control 
qualification. In 1994 a subspecialty for physicians was also instituted. Additionally, various 
training courses for the prevention of HAIs and AMR are available to healthcare workers 
annually. 
 
 
2.5 Monitoring of antimicrobial consumption 
2.5.1 Antibiotic consumption data monitoring 
Antimicrobial consumption in the community (primary care sector) in Finland has been stable 
over the last 10 years. The Finnish consumption of antibiotics in 2010 was 18.5 Defined Daily 
Doses (DDDs) per 1 000 inhabitants and per day, which is at the same level as the ESAC-Net 
median (18.3) of participating countries from 2010. 
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2.5.2 Antibiotic treatment guidelines and monitoring of compliance 
 
Updated national guidelines are available and published on the internet for the diagnosis and 
management of the six most common community infectious diseases. After inquiry with 
physicians during the visit, these guidelines appear to be well known and used by most 
physicians in primary care. Recent specific data and/or analyses of the physician compliance 
with antibiotic prescribing with these guidelines are not, however, available.  
 
2.5.3 Monitoring of antibiotic consumption 
Antibiotics are available in Finland only through prescription and no over the counter sales 
are permitted. Two institutions monitor antibiotic use in Finland: The Finnish Medicines 
Agency (FIMEA) and the Social Insurance Institution of Finland (KELA).  
 
FIMEA is the national competent authority for regulating pharmaceuticals. FIMEA provides 
data to the European Surveillance of Antimicrobial Consumption Network (ESAC-Net) on 
antibiotic consumption and these data are sales data. The sales figures of the register are 
based on the sales of the two largest medical wholesalers in Finland. The register does not, 
however, include any information on antibiotic use or indication for prescription and therefore 
there is no possibility, amongst others, for feedback to physicians. 
 
KELA, the Social Insurance Institution of Finland, operates under the oversight of the Finnish 
Parliament. Its administration and operations are overseen by 12 Trustees selected by 
Parliament and by 8 Auditors selected by the Trustees. 
Kelasto is a statistical database produced by KELA, with which custom reports from the 
statistical data compiled by KELA can be created. Data for reimbursable outpatient 
prescriptions are available up until 2011. Kelasto collects data on variables for each 
prescription, e.g. customer (age, sex, medication purchase history), presence of a number of 
diseases required for special reimbursement, physician (several categories including training, 
age), prescription date, medication (e.g. active substance, trade name, dose, package size), 
pharmacy and purchase date. 
 
Data reporting and collection on indications for the prescription are not, however, mandatory 
and therefore KELA cannot provide information about antibiotic use by indication, nor can it 
calculate the consumption of antibiotics in outpatient care. 
It is notable that, whereas data from these two organisations are collected centrally the 
submission of the data is not mandatory. This makes it difficult to evaluate the information 
that is fed back to healthcare districts, physicians and healthcare centres, as it may not be 
complete. The goal of providing detailed feedback is to improve prudent antimicrobial use, 
also to do so correlating it with local resistance patterns in order to improve practices. 
 A www-based database on certain prescription categories is available and individual 
physicians receive annual reports from KELA on their prescriptions 
(http://raportit.kela.fi/ibi_apps/WFServlet).  
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3 Observations 
3.1 Development of an Intersectoral Coordinating 
Mechanism (ICM) 
Three national coordination groups for antimicrobial resistance have been formed in Finland. 
The formation of these groups, otherwise known as the ICM is in accordance with 
recommendations from the Council Recommendation on the prudent use of 
antimicrobial agents in human medicine (2002/77/EC). 
 
The first ICM was formed in 1999 when a fixed-period working group on AMR was appointed 
by the MSAH. The published output of this working group was a report published in 2000, 
which contained 8 specific recommendations. After the dissolution of this working group, 
another national working group came together from 2008-2010, which met five times in 
those two years and whose published output was a report that reviewed activities for AMR 
implemented in Finland between 2000 and 2010.  
 
The current ICM (National Advisory Committee on Antimicrobial Resistance Prevention) is a 
multi-sectoral committee, which was formed in April 2012 and has a life expectancy until 
2015. The Director General of THL gave a mandate for the formation of this committee and 
identified the relevant stakeholders who would be a part of it and the stakeholders appointed 
the individual members. The composition of the group includes members from THL, the 
Finnish Food Safety Authority (EVIRA), the Social Insurance Institution of Finland (KELA), the 
Finnish Medicines Agency (FIMEA), infectious disease physicians, laboratory professionals, the 
Ministry of Social Affairs and Health, the Ministry of Agriculture, hospital districts, university 
and regional hospitals, amongst others. Its main goals are to look at previous 
recommendations, current needs, expert opinion, establish a strategy for the working group, 
increase awareness for AMR and to increase the collaboration between human and animal 
sectors. 
 
Despite the fact that this committee was formed with the support of THL and the MSAH, it 
does not appear to have a concrete, well-delineated role. It has no clear mandate, tasks or 
responsibilities, and has not yet outlined a strategy for the purpose of addressing the rise in 
AMR. Furthermore, it has no dedicated budget and to date it has only met two times in 2012. 
There is no known plan whether HAIs will also be addressed by this committee, or whether a 
separate committee will be formed.  
 
3.2 Laboratory capacity  
Every hospital district is served by at least one microbiology laboratory in which a medically 
trained microbiologist is always part of the staff. There are approximately 25 major clinical 
microbiological laboratories in Finland. University microbiology laboratories serve the 
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university hospitals and the neighbouring district as well as any other municipalities willing to 
purchase their services. All clinical microbiology laboratories are required to have a license, 
which is renewed every three years. The renewal conditions include, amongst others, regular 
participation in rounds of external quality assurance testing.  
All university hospital microbiology laboratories that ECDC visited had their own budget lines 
with their own Boards. As an example, there were 1.2 million tests performed on an annual 
basis by microbiology laboratories for a population of 1.5 million people in the Helsinki district. 
Even though the bulk of microbiological and molecular testing is performed in the health 
district laboratories, there is a trend for externalization and/or privatization of laboratories. 
Such private laboratories process a small proportion of microbiology samples from a subset of 
patients from the healthcare districts; this trend is not widespread at present. 
 In all laboratories that ECDC visited, the reported turn-around time for results of 
microbiological culture and antimicrobial susceptibility testing is within 48 hours or faster if 
requested. Positive blood cultures results were reported in a timely fashion and results and 
notification of alert organisms were communicated directly to the infection control team or a 
responsible individual. Overall, there appears to be good communication and notification from 
the laboratory to infection control teams in the hospital districts.  
For epidemiological purposes, all isolates of a number of specified antimicrobial-resistant 
microorganisms are submitted to THL for further molecular sub-typing free of charge. The 
initial diagnostic testing is funded by the hospitals and clinical microbiology laboratories, but 
all typing/sub-typing of the isolates of specified resistant microorganisms that are 
systematically submitted to THL, is free of and covered by THL funding.  
 
 
3.3 Antibiotic resistance in select alert organisms 
3.3.1 Meticillin-resistant Staphylococcus aureus (MRSA) 
 
Data on the percentage of MRSA were not reported to EARS-Net from Finland for 2011, but 
previous data from 2010 show a percentage below 3% for MRSA. Some areas in Finland 
report higher percentages than the national average and these areas clearly represent 
reservoirs for spread to surrounding areas. Many of these areas, or health districts, have had 
increasing incidence of MRSA and hospitals and LTCFs have become endemic, with 
interchange of MRSA patients between such healthcare settings. This demonstrates the slow 
rise of prevalence of MRSA despite local infection control measures implemented by 
healthcare settings.  
 
An example of the above is an MRSA outbreak in Pirkanmaa, which started in 2002 involving 
the Tampere City, Tampere University Hospital and the surrounding healthcare settings. Two 
initial attempts to stop the outbreak were made through isolated projects, including one that 
was stopped because of the lack of financial support. This has now resulted in an endemic 
situation in the health district (hospitals and LCTFs). From 2011, in the university hospital a 
new approach has been initiated including numerous and resource-demanding infection 
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control measures in an effort to curb the rising incidence, including active screening of 
patients.  
It is evident from this evolution of outbreaks to an endemic situation that a national strategy 
for infection control, including management of outbreaks and HAIs and a nationally 
responsible body oversee the full epidemiological pictures of the country, are needed. Local 
ID physicians are have identified the need for a common strategy in all healthcare settings 
and health districts and have also stated that adequate funding is necessary to uniformly 
address the problem across the country. 
 
3.3.2 Extended-spectrum beta-lactamase (ESBL)-producing 
Enterobacteriaceae 
The prevalence of other resistant bacteria, e.g. ESBL-producing Enterobacteriaceae, in 
Finland has increased in the past few years, in an exponential fashion, doubling to over 4% 
in Enterobacteriaceae isolates. This trend is seen at a national level, but is also observed 
locally in hospitals and LTCFs. 
All data shown locally and nationally demonstrate a fast-rising prevalence of ESBL-producing 
Enterobacteriaceae during the last years. The same trends can be seen in national data from 
FiRe and in invasive bloodstream isolates reported to EARS-Net (from below 2% to over 4%) 
as well as trends from other EU Member States. Molecular typing is performed on some 
isolates and older data show that many of these resistant isolates were due to the presence 
of CTX-M-15, especially in community-acquired urinary tract infections, which is a global 
trend. There is no specific strategy or jointly agreed guidelines for the control of ESBL-
producing Enterobacteriaceae in healthcare settings despite this constant increase in 
prevalence. Transmission between LCTFs and hospitals is a particular concern and has not 
been clearly addressed yet. 
3.3.3 Carbapenemase-producing Enterobacteriaceae (CPE) 
Data from EARS-Net from 2010 show no carbapenem-resistant Enterobacteriaceae BSI isolate 
in Finland. Data from individual hospitals, however that were presented during the visit, show 
that there are reported cases of CPE and that these cases involve all types of 
carbapenemases. Most cases appear to be imported, although some cases were reported as 
autochthonous. Experience from other countries shows that EARS-Net data represent only 
the tip of the iceberg (and also represent only BSIs). Generally, even a few cases can lead to 
spread if tight control measures are not implemented and infection control guidelines are not 
created. There is no official specific infection control action plan for the control of spread of 
CPE although hospitals have developed their own strategies based on international 
recommendations. The hospitals that were visited during the country visit all performed 
screening for CPEs when patients were transferred from any a healthcare facility in another 
country. 
 
 
 
 
 
 
ECDC country visit to discuss AMR issues COUNTRY VISIT REPORT 
 
 
 
22 
 
 
 
 
3.4 Infection control 
3.4.1 Role of healthcare professionals 
The ECDC team visited University hospitals in Helsinki, Turku and Tampere, community 
healthcare centres and long-term care facilities (LTCF). The ECDC team met with many 
infectious disease (ID) physicians, many of whom were both infection control (IC) and ID 
physicians, and with IC practitioners (ICPs). ICPs and IC and ID physicians were present in 
both larger municipalities and hospitals and smaller municipalities frequently had part-time 
ICPs. In many of the community healthcare centres, IC nurses were present, and IC 
physicians were either also employed, or were dispatched regularly or, as needed, from the 
hospital. It was apparent that there was a lack of full-time equivalent physicians to perform 
IC duties in some hospitals and in the respective region. Because of these many roles, 
workflow for IC and ID physicians became fragmented. 
In the past decade, the number of ID physicians and ICPs has increased and the ECDC team 
was informed that this might have been due to the increased awareness of the role of 
infectious diseases in health care settings due to the rise of AMR. 
 
Despite the fact that in healthcare settings there was a strong presence of ICPs, IC and ID 
physicians, the authority and ability of the infection control committees to intervene and 
make clear decisions based on data was unclear and differed from setting to setting. Similarly, 
the involvement of hospital administrators was also not well defined or consistent everywhere.  
 
As HAI reporting is not mandatory, the decision-making for how to diagnose, report and how 
HAI rates are fed back to physicians and hospital administrators is up to the hospital itself. 
Front line ICPs (IC physicians and nurses) are aware of the need to prevent AMR and HAIs 
and are very actively involved in creating and implementing guidelines for the hospitals, 
participating in infection control committees and striving towards prudent use of antibiotics. 
Reporting of HAIs, however, appears to be mostly based on passive surveillance and self-
reporting of HAIs by physicians, rather than active surveillance. 
 
3.4.2 Multidrug-resistant organisms (MDROs) and active screening 
Discussions at hospitals and LTCF focused mostly on MRSA and only minimally on Gram-
negative bacteria. Infection control practices differed between hospitals and seemed to 
depend upon the individual hospital initiative and awareness of their local situation. In 
addition, there was no homogeneity in the strategies present in hospitals for dealing with 
different types of MDROs, and, in some of the visited healthcare settings, there was a lack of 
adequate structures for isolations such a single beds and individual toilets 
 
Because of the increased importance given to the increasing MRSA incidence in some areas in 
Finland, much of the infection control focus is on MRSA and guidelines for the control of 
other MDROs (e.g. ESBL-producing Enterobacteriaceae) appear underdeveloped or not as 
clearly defined and were up to the individual hospital initiative to identify these as a problem. 
Within the same health district there was good communication between hospitals when 
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patients were transferred as to whether they were colonised or infected with MRSA, but this 
communication did not exist beyond the health district (as the patient record computer 
systems differ between health care districts). There was concern about the further spread of 
resistant bacteria into hospitals from other countries and also between healthcare districts 
with different practices, when the cross-border initiative is fully implemented in the future. 
Active screening of patients was discussed in all hospitals and healthcare settings the ECDC 
team visited. When asked about active screening of high-risk patients, there was no uniform 
system for evaluating high-risk patients for any of the alert organisms and this was up to the 
individual hospitals, again most of the emphasis was placed on MRSA.  
 
3.4.3 Monitoring of prudent antibiotic use in hospitals 
Ensuring prudent use of antibiotics in the hospitals that were visited was mostly done by 
consultation of ID physicians and their involvement in patient care. In many hospitals there 
are multidisciplinary teams that promote antibiotic use but there appeared to be no uniform, 
formalised strategy to evaluate antibiotic utilisation by measuring defined daily doses (DDDs) 
or any other method. The introduction of the concept of a multi-disciplinary committee in the 
form of “antibiotic stewardship committee” which would involve pharmacists, pre-approval of 
antibiotics, involvement of pharmacy and antibiotic utilisation and monitoring, was met with 
interest. In many hospitals, this task is currently given to the infection control committee of 
that facility. 
 
3.4.4 Hand hygiene 
Throughout all healthcare settings there was widespread availability and use of alcohol-based 
hand rub by all healthcare workers (HCWs). Posters campaigning for hand hygiene were 
homogenously present throughout the hospitals and health centres. In some settings patient 
empowerment for compliance with hand hygiene by HCWs was promoted.  
 
3.4.5 Long-term care facilities (LTCFs) 
A few LTCFs were visited during the country visit. Data were presented mostly on the 
prevalence of MRSA and ESBL-producing Enterobacteriaceae. In most LTCFs the incidence of 
ESBL-producing Enterobacteriaceae was on the rise, mirroring the picture that is seen for 
Finland from EARS-Net data, but also for the rest of Europe. There was an increased 
prevalence of MRSA also in all settings. Despite this worrisome picture of increasing 
resistance, it was interesting that LTCFs were not actively thought of as important reservoirs 
for the importation of resistant bacteria into hospitals. Active screening of these patients is 
currently not routinely performed upon hospital admission. The focus of infection control in 
LTCFs was mostly on the control of MRSA, even though incidence data both on MRSA and 
ESBL-producing Enterobacteriaceae were presented. Contact precautions and patient 
cohorting were used due to the increased incidence (reaching endemic status in a few places). 
It was communicated that it is extremely difficult to implement adequate infection control 
measures in LTCFs due to the nature of the residents’ psychosocial factors. 
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3.4.6 Active patient screening for MDROs 
High-risk patients, those who are at high-risk for being colonised with MDROs, are considered 
those who are either returning from abroad, cross-border transfers from healthcare-settings, 
or those who are from countries outside of Finland. Active screening for MRSA, ESBL-
producing Enterobacteriaceae, VRE and CPE is suggested for these patients upon admission 
to the hospital and is considered “best practice”.  
The risk associated with other types of patients, such as those who are admitted from LTCFs 
and especially from LTCFs with known high prevalence of MDROs, has not been fully decided 
upon and there has been considerable debate about how to proceed and make 
recommendations. At present, it is mostly up to individual hospitals to decide when and if to 
perform active screening. 
 
3.5 Educational programmes on AMR 
This was not discussed in depth. In general, however, ID physicians and nurses appear to 
provide education and updates on antibiotic stewardship and IC measures to other healthcare 
workers in the community and hospitals and advice, guidance and education is provided at 
the point of care through consultations. Annual training courses on AMR and IC are organised 
for healthcare workers, which are well attended. 
 
3.6 Public information related to AMR 
Information about attitudes of the public towards antibiotics was assessed through the 2009 
Eurobarometer survey 
(http://ec.europa.eu/health/antimicrobial_resistance/docs/ebs_338_en.pdf). The results 
demonstrated that level of awareness in the Finland was higher than the EU average. As per 
the information given to us by all stakeholders, the media actively publicised healthcare-
associated outbreaks and the issue of AMR and HAIs.  
 
3.7 Marketing related issues 
This topic was not addressed during the course of the country visit. We were informed, 
however, that FiRe was partly funded by the pharmaceutical industry due to lack of other 
resources. 
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4 Conclusions and recommendations 
4.1 Conclusions 
Organisation of healthcare system 
The Finnish health system appears to be well organised and equipped, with a good 
infrastructure, laboratory capacity, physicians and nursing staff who are sensitised about 
issues surrounding AMR and HAIs and who provide quality care to patients.  
 
Legislation for AMR and HAI 
The legislation for AMR and HAIs falls under the Communicable diseases Act 504/1986, the 
Communicable Diseases Decree 786/1986, the Health Care Act 30.12.2010/1326, the Health 
Care Decree 341/20. At present this Act, however, does not include a section for a national 
strategy for the prevention of AMR and HAIs. The Communicable Disease Act and Decree are 
undergoing revision and a reorganisation of the healthcare structure is in progress. Specific 
legislation for AMR and HAIs will be included in the new legislation.  
 
Intersectoral Coordination Mechanism (ICM) 
The current National Advisory Committee on Antimicrobial Resistance Prevention is a multi-
sectoral committee that has the role of an ICM and has a life expectancy until 2015. This 
committee does not appear to have a well-delineated role, as it has no clear mandate, 
responsibilities and has not yet outlined a strategy to address the rise in AMR. Furthermore, it 
has no dedicated budget. It is also not known whether HAIs will also be addressed by this 
committee or whether a separate committee will be formed for this purpose. 
 
 
Antimicrobial resistance in Finland  
Rates of bacteria that are resistant to antimicrobials are low, but are slowly rising. There is 
clear interchange and spread of resistant bacteria between healthcare settings and has been 
identified as a rising problem. Management of this increase, starting from hospital outbreaks 
and leading to establishment of an endemic situation in some healthcare settings, has been 
addressed mostly at the local, hospital level and infection control measures are not 
homogeneously implemented across the country. More specifically, the following observations 
were made for specific multidrug-resistant organisms (MDROs): 
 MRSA 
Data on the prevalence of MRSA were not reported to EARS-Net from Finland 
for 2011, but previous data from 2010 show 3% prevalence with some areas 
reporting higher numbers, clearly represent reservoirs for spread to 
surrounding areas. Many of these areas, or health districts, have had an 
increasing incidence with interchange of MRSA patients between healthcare 
settings. This demonstrates the slow rise of prevalence of MRSA despite local 
infection control measures implemented by healthcare settings. It is evident 
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from this evolution of outbreaks to an endemic situation, that a national 
strategy on infection control is needed.  
 
 ESBL-producing Enterobacteriaceae 
The incidence of other resistant bacteria, e.g. the ESBL-producing 
Enterobacteriaceae in Finland has increased in the past few years, in an 
exponential fashion, doubling to over 4%. This trend is seen at a national 
level, but is also observed locally in hospitals and LTCFs. There is no specific 
strategy or national guidelines for the control of ESBL-producing 
Enterobacteriaceae in healthcare settings despite this constant increase in 
incidence, nor is the issue of transmission between LCTFs and hospitals 
addressed, according to observations. 
 
 CPE 
Bacteria that are resistant to almost all available antibiotics, e.g. CPE, have 
been reported and their incidence is slowly rising. This poses a significant 
future risk that needs to be mitigated, and even though most of these isolates 
imported they have the propensity to spread through healthcare systems once 
introduced. There is no official specific infection control action plan for the 
control of spread of CPE although hospitals can develop their own strategy. 
 
Healthcare-associated infections 
  
In Finland, surveillance for HAIs in all hospitals is not mandatory, but rather voluntary. 
Hospitals can voluntarily participate and report to SIRO where uniform surveillance data are 
collected for certain surgical site infections and for bloodstream infections, using standardised 
HAI case definitions. Although SIRO involves a large number of hospitals, not all hospitals in 
the country currently participate. For hospitals that do not participate in SIRO, case 
definitions and data reporting are not uniform and reporting to a national body is not 
performed. Finnish point prevalence surveys (PPSs) have been performed in the past, and 
the last one was published in 2005. The last data on HAIs are from 2006. Annual and timely 
data are not available at present from SIRO. Most recently, in 2011, Finland performed a PPS, 
as part of the ECDC PPS, during which all hospitals involved used uniform case definitions.  
 
 
Infection control 
The spread of resistant bacteria like MRSA, ESBL-producing Enterobacteriaceae and CPE, all 
MDROs, should be regarded as a threat to patient safety. As HAIs are under the responsibility 
of the hospital districts, there are no mandatory legal requirements for infection control 
structures and processes in hospitals. Hospitals, therefore, create, adopt or adapt available 
international guidelines and/or recommendations from the Finnish Infection Control Society 
manual. This has led to the development and practice of different approaches within and 
between health districts and municipalities. Furthermore, hospitals had developed 
heterogeneous strategies for the approach of infection control measures for different types of 
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MDROs. Infection control practices differ between hospitals and hospital control of infections 
depended on local initiatives depending on the awareness of the situation, the organisation 
and the financial resources available. 
 
In healthcare settings the presence of infection control physicians and nurses was very strong. 
They are extremely aware of the issues of AMR and HAIs, but feel that they need to have the 
more authority to intervene and for infection control committees to make more fundamental 
changes and to make decisions based on feedback of timely data. Although in many of the 
hospitals visited, the hospital administrator was either interested or involved in infection 
control, front line workers stressed that adequate resources were necessary to implement a 
complete strategy. 
 
At a national level, there appears to be no coordinating body that has full responsibility of 
addressing this rise in resistance, outbreaks and the monitoring of AMR and HAIs in Finland 
as a whole. THL is involved at many stages of diagnoses, data collection and voluntary advice, 
but it has no risk management role and is not formally designated to intervene.  
In some countries in Europe, examples of which are the United Kingdom and France by 
creating a legal infrastructure have been able to empower monitoring bodies and healthcare 
structures to implementation and monitor national strategies for AMR and HAIs. 
 
 
LTCFs 
While visiting LTCFs, data were presented mostly on the prevalence of MRSA and ESBL-
producing Enterobacteriaceae. There was an increased prevalence of MRSA in all settings. In 
most LTCFs, the incidence of ESBL-producing Enterobacteriaceae was on the rise, mirroring 
the picture that is seen for Finland from EARS-Net data, but also for the rest of Europe. 
Despite this worrisome picture of increasing resistance, LTCFs were not actively considered 
as important reservoirs for the importation of resistant bacteria into hospitals. Active 
screening of these patients is currently not routinely performed upon hospital admission. The 
focus of infection control in LTCFs mostly centred around the control of MRSA, even though 
incidence data both on MRSA and ESBL-producing Enterobacteriaceae were presented. It was 
communicated that it is extremely difficult to implement adequate infection control measures 
in LTCFs due to the nature of the residents’ psychosocial factors. 
 
Antibiotic use and monitoring 
Two institutions monitor antibiotic use in Finland: the Finnish Medicines Agency (FIMEA) and 
the Social Insurance Institution of Finland (KELA). Data reporting and collection on 
indications for the prescription are not, however, mandatory and no data can be obtained 
about antibiotic use by indication, nor can calculations be made for the consumption of 
antibiotics in outpatient or inpatient care. 
It is notable that, whereas data from these two organisations are collected centrally, the 
submission of the data is not mandatory. This makes it difficult to evaluate the information 
that is fed back to healthcare districts, physicians and healthcare centres, as it may not be 
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complete. The goal of providing detailed feedback is to improve prudent antimicrobial use, 
also to do so correlating it with local resistance patterns in order to improve practices. 
 
EU Cross-border healthcare Directive  
The EU Cross-border healthcare directive will allow patients to choose their own treatment 
facility. This will mostly probably increase the movement of patients within Finland and across 
borders. Finland has long borders with Russia and may need to consider what implications 
this might have on AMR. 
 
 
 
4.2 Recommendations 
Legislation for AMR and HAI 
 There is a need for an overview of the current legislation on infection control, which 
could be compared to similar legislations in other European countries. In some 
countries in Europe, examples of which are the United Kingdom and France, the 
creation of a legal infrastructure has been able to empower monitoring bodies and 
healthcare structures to implementation and monitor national strategies for AMR and 
HAIs. 
 Included in this legislation could be a clear mandate and budget for the ICM, the 
creation and implementation of national strategies and action plans for AMR and 
HAIs, having a specific responsible body for the oversight and using structure and 
process indicators to monitor the implementation of the strategies. 
 
 
National strategies for AMR and HAI 
 It is essential that prevention and control of AMR and HAIs in Finnish hospitals, in 
other healthcare facilities and the community be strengthened. Efforts to control this 
rise must involve all stakeholders at all levels, national and local.  
 It would be important to develop and implement a national action plan, national and 
local guidelines for AMR, prudent use of antibiotics and the prevention of HAIs.  
 Responsibility for combating AMR and HAIs in Finland should be clearly assigned to a 
national overseeing body that will coordinate, monitor and have the overall 
responsibility for this. Legal authority and responsibility should be assigned to this 
body and be exercised. 
 This overseeing body should also follow indicators that monitor the implementation of 
the strategies for AMR and HAIs. 
 Communication between all relevant parties and collaboration should be enhanced 
with regard to the overall status of AMR and HAIs in Finland. 
 
Intersectoral Coordination Mechanism (ICM) 
 There is a need to empower the current ICM. It should have strong political 
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endorsement and support and should be given a clear mandate and dedicated 
budget. 
 The ICM could, as part of its mandate, develop national strategies and action plans 
for the control AMR and HAIs and monitor their implementation. The ICM could also 
evaluate the impact of resistance on health and economic outcomes. 
 
Infection control and surveillance 
 
 It is important to strengthen the role of infection prevention and control practitioners 
(ICPs) and infectious disease (ID) physicians in hospitals and their involvement in 
diagnosing and collecting data on HAIs. 
 To ensure implementation of strategies and action plans for AMR and HAIs, front-line 
ICPs and healthcare workers should be empowered and indicators created and 
monitored at a local and national level. 
 Active surveillance of HAIs in hospitals should be enhanced and data fed back in a 
timely manner to ICPs and ID physicians in hospitals to be able to monitor their HAI 
rates and make appropriate interventions. 
 Hospital administrators should be involved in the regular meetings of the infection 
control committee and the HAI rates fed back to them to improve infection control 
practices and provide adequate resources for their prevention.  
 Data on HAI could be collected in a systematic and timely fashion and from more 
hospitals and reported to SIRO, allowing for timely information and more complete 
epidemiological data. 
 
Antibiotic use 
 Measurement of antibiotic use in the community according to indication could be 
obtained by optimal use of indication data from KELA. Ways to also obtain such data 
from FIMEA could be considered.  
 Prudent use of antibiotics should be strengthened by formation of multidisciplinary 
antibiotic monitoring teams in hospitals led by infectious disease physicians.  
 Feedback of data on antibiotic use could be fed back to physicians at the hospital level 
and the community level for improvement of prescribing practices. 
 
 
Epidemiological overview for AMR and HAIs 
 Integrating epidemiological work as a part of the health system would strengthen the 
efforts to contain AMR. Data could be analysed systematically, timely and reviewed 
continuously and lead to necessary actions.  
 Active communication of the overall conclusions and analysis to all hospital districts, 
relevant national institutions, the public and the Ministry is important.  
 To enhance the epidemiological analysis of the current and future status of AMR it is 
important to use molecular methods to monitor the spread of MDROs. Molecular 
typing, which is an essential component for epidemiological analysis and can pose a 
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financial burden, could become a problem in the future if the burden of AMR and HAIs 
increases. 
 
Annual reporting of joint human and veterinary report 
 An annual, joint human and veterinary report on prevalence of AMR from humans and 
animals is suggested. Annual reporting to EARS-Net is suggested and necessary 
resources should be allocated for this purpose. 
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5 Appendices 
 
5.1 ECDC Team 
 Anna-Pelagia Magiorakos, ECDC 
 Nabil Safrany, ECDC 
 Peet Tüll, External consultant, Sweden 
 
5.2 Persons met 
ECDC EFSA AMR COUNTRY VISIT TO FINLAND (Oct 28th-Nov 2nd, 2012 
Date and time ACTIVITY (topic, site, persons to meet) 
MONDAY (Oct 29th) DAY ONE (JOINT PROGRAM FOR ECDC AND EFSA TEAMS, location HELSINKI) 
8.30-15.30 INTRODUCTION TO AMR FUNCTIONS IN FINLAND 
Site: National Institute for Health and Welfare (THL) 
Address: Mannerheimintie 166, 00300 Helsinki, Building A, Meeting room Collegium (A5) 
9.00-9.15 Welcome Address 
o Prof. Pekka Puska (THL, Director General) 
o Dr. Anni Virolainen-Julkunen (MSAH, Senior Medical Officer) 
9.15-9.45 Ministry of Social Affairs and Health and Ministry of Agriculture and Forestry (MAF) 
o Dr. Anni Virolainen-Julkunen (MSAH, Senior Medical Officer) 
o Dr. Leena Räsänen (MAF, Veterinary Counsellor) 
9.45-10.15 National Institute for Health and Welfare (THL)  
 Overview and discussion on activities related to IDs at THL  
o Prof. Petri Ruutu (THL, Head, Dept. of Infectious Disease Surveillance and 
Control) 
o Prof. Juhani Eskola (THL, Deputy Director General)  
10.15-10.35 National Advisory Committee on Antimicrobial Resistance Prevention 
 Multisectoral committee on surveillance, guidance and prevention of 
AMR. Established 2012. 
o Prof Jaana Vuopio (Chairperson of the Committee) 
10.35-11.05 Finnish Study Group for Antimicrobial Resistance (FiRe) 
 A coalition of the Finnish clinical microbiology laboratories and the THL 
bacteriology units on AMR surveillance. Established 1991. Webpage:  
o Dr. Antti Hakanen (Co-ordinator of the Study Group) 
11.05-11.30 The Finnish Society on Hospital Infections 
 A non-profit professional society to promote issues on hospital 
infections, including training. Established in 1960s. 
o Dr. Mari Kanerva (Chairperson of the Society) 
12.30-14.45 Role of THL in AMR and infection control (IC):  
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12.30-13.00 National Infectious Disease Register (NIDR) 
 Description of structured ID notification system (physicians and clinical 
microbiological laboratories), established 1995. Annual report (year 
2010):  
o Dr. Markku Kuusi (THL, Head, Unit of Epidemiologic Surveillance and 
Response) 
13.00-13.30 THL Reference Laboratories and National licensure system for clinical microbiological 
laboratories  
 Overview on bacteriological and virological laboratory activities at THL 
and description of licensure process. 
o Prof. Anja Siitonen (THL, Head, Unit of Bacteriology) 
o Dr. Mika Salminen (THL, Head, Unit of Virology) 
13.30-14.00 Finnish Healthcare-Associated Infections Programme (SIRO) 
 Overview of activities of nationwide HAI surveillance program in relation 
to AMR and IC, established 1997. 
o Dr. Outi Lyytikäinen (THL, Head of program) 
14.30-15.00 Finnish Medicines Agency (FIMEA) 
 Sales of antibiotics for human use 
o Dr. Annikka Kalliokoski (FIMEA, Senior medical officer) 
 
15.00-15.30 The Social Insurance Institution of Finland (KELA) 
 Antibiotic prescriptions and reimbursements 
o Dr. Lauri Keso (KELA, Medical advisor) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Name First Name Title Position Affiliation 
Day One 
Puska Pekka Pr Director General THL 
Virolainen-Julkunen Anni Dr Senior Medical Officer MSAH 
Räsänen Leena Dr Veterinary Counsellor MAF 
Ruutu Petri Pr Head of Dpt THL - Dpt of Infectious Disease Surveillance and Control 
Eskola Juhani Prof Deputy Director General THL 
Vuopio Jaana Prof Chair National Advisory Committee on Antimicrobial Prevention 
Hakanen Antti Dr Coordinator FiRE 
Kanerva Mari Dr Chair Finnish Society on Hospital Infection Control 
Kuusi Markku Dr Head of Unit THL - Unit of epidemiological surveillance and response 
Siitonen Anja  Prof Head of Unit THL - Unit of Bacteriology 
Salminen Mika Dr Head of Unit THL -Unit of Virology 
Lyytikäinen Outi  Dr Head of programme THL, Finnish Hospital Infection Program, SIRO 
Kalliokoski Annikka  Dr Senior medical officer FIMEA 
Keso Lauri Dr Medical advisor KELA 
Vuorela Marjo    Infectious Disease fellow  THL 
Polkowska Aleksandra  Mrs EPIET fellow THL 
Smit Pieter Mrs EUHEM fellow THL 
Järvimäki Saija Mrs   THL - Communications and Customer Relations Unit 
Day two 
Ekujansu Erkki Dr Administrative medical director Tamere University Hospital - TAUH 
Syrjänen Jaana Dr Head of Infectious Diseases TAUH 
Vuento Risto Dr Laboratory director FIMLAB 
Arvola Pertti Dr Infectious diseases TAUH 
Huttunen Reeta Dr Infectious diseases TAUH 
Laine Janne Dr Infectious diseases TAUH 
Vuorihuhta Minna Mrs IC Nurse TAUH 
Räsänen Sirpa Dr Epidemiologist City of Tampere 
Aittoniemi Janne Dr Deputy chief FIMALB 
Karlsson Sari Dr Chief physician TAUH – ICU ( 
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Karhe Liisa Mrs Head nurse TAUH - ICU 
Aho Hanna Mrs Head nurse TAUH - Hand and plastic surgery 
Göransson  Harry Dr Head of Hand and Microsurgery TAUH 
Suojalehto Ella   Director - Head of hospital and institutional care   
Ripsaluoma Jussi Dr Chief physician Rauhaniemi hospital 
Viik Marjo  Dr Senior physician Kauppi hospital 
Taskinen Kirsti Mrs Head nurse Kauppi hospital 
Höglund Ulla-Maija Mrs IC Nurse Koukkuniemi Home of the Elderly 
Levänen Reetta Mrs Nurse Kauppi hospital 
Leppänen Leena Mrs Nurse Koukkuniemi Home of the Elderly 
Day three 
Huovinen Pentti Pr Professor of Bacteriology Turku University Medical School 
Jalava Jari  Dr Senior lecturer  Turku University Medical School 
        Vice unit head - Antimicrobial susceptibility testing-group 
Hakanen Antti Dr Senior lecturer  Turku University Medical School 
Vuopio Jaana  Pr Head of Unit THL - AMR Unit 
Soini Hanna  Dr Vice Unit Head THL - AMR Unit, Mycobacteria group 
Österblad Monica Dr Senior researcher THL - AMR Unit, Antimicrobial susceptibility testing-group 
Lindholm  Laura Ms Senior researcher THl - AMR Unit, Hospital bacteria-group 
Rintala  Esa  Dr Head of Hospital Hygiene and Infection Control Turku University Hospital  
Marttila  Harri  Dr Specialist in Infectious Diseases Turku University Hospital  
Meurman  Olli Dr Director TYKSLAB 
Tantakokko-Jalava Kaisu Dr Chief physician TYKSLAB 
Routamaa Marianne Mrs IC Chief nurse Turku University Hospital  
Hohenthal  Ulla    Specialist of Infectious Diseases Turku University Hospital  
Rautio Sari Mrs Head nurse Turku University Hospital  
Marttila Jane  Dr Epidemiologist On-Call Service of the Health - City of Turku 
Haapasaari  Marjo  Mrs IC Nurse On-Call Service of the Health - City of Turku 
Varvikko Jukka Dr Specialist in general practice On-Call Service of the Health - City of Turku 
Rantala Arto  Dr Chief Specialist in Surgery  Surgical Hospital of Turku University Hospital  
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Day four 
Mäkijärvi Markku  Dr Medical director  Helsinki University Hospital  
Järvinen Asko  Dr Head of Infectious Diseases  Helsinki University Hospital  
Kolho Elina  Dr ID Consultant  Helsinki University Hospital  
Kanerva Mari  Dr Chief Physician - Infectious diseases  Helsinki University Hospital  
Salo Eeva Dr Chief Physician, Pediatric Infectious Diseases  Helsinki University Hospital  
Vaara Martti Dr Head, Division of Clinical Microbiology  HUSLAB 
Aalto Anu  Ms IC Nurse Helsinki University Hospital  
Kaartinen Johanna Dr Chief Physician - Infectious diseases  Helsinki University Hospital emergency department and ICU  
Anttila Veli-Jukka  Dr Chief physician, Infectious Diseases Helsinki University Hospital - hematology ward  
Volin  Liisa Dr   Helsinki University Hospital - hematology ward  
Honkanen-Buzalski Tuula Prof Director EVIRA 
Raulo Saara Dr Coordinator EVIRA - Finish Zoonoses Centre 
Helin-Soilevaara Henriette Dr Senior officer EVIRA 
Myllyniemi Anna-Liisa Dr Head of Unit EVIRA - Food and Feed Microbiology Research Unit 
Räsänen Leena Dr Veterinary Counsellor MAF 
Aho Matti Dr Director General EVIRA 
Day five 
Sillanaukee Päivi  Dr Permanent Secretary MSAH 
Hansson Aino-Inkeri  Mrs Director-General for Promotion of Welfare and Health MSAH 
Virolainen-Julkunen Anni  Dr Senior Medical Officer MSAH 
Puumalainen Taneli  Dr Senior Medical Officer MSAH 
Niemi Veli-Mikko  Mr Director of Food Safety MAF 
Räsänen Leena Dr Veterinary Counsellor MAF 
Ruutu Petri Pr Head of Dpt THL - Dpt of infectious disease surveillance and control 
Koivisto Taru    Director MSAH - Health Promotion Group 
Vuopio Jaana Prof Chair National Advisory Committee on antimicrobial prevention 
Lyytikäinen Outi  Dr Head of programme THL, Finnish Hospital Infection Program, SIRO 
        Vice unit head - Antimicrobial susceptibility testing-group 
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Jalava Jari  Dr Senior lecturer  Turku University Medical School 
Hakanen Antti Dr Coordinator FiRE 
Myllyniemi Anna-Liisa Dr Head of Unit EVIRA - Food and Feed Microbiology Research Unit 
Syrjänen Jaana Dr Head of Infectious Diseases TAUH 
Raulo Saara Dr Coordinator EVIRA - Finish Zoonoses Centre 
Mikko Paunio Dr   MSAH 
Ollila Liisa  Mrs Director - international affairs MSAH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
5.3 Assessment tool for ECDC country visits to discuss 
antimicrobial resistance (AMR) issues 
The mechanisms behind emerging AMR are complex. However, two main issues that stand out offering 
opportunity for control efforts are: the use of antibiotics and the epidemiological spread of resistant 
microbes.  
The complexity of the problem makes it difficult to grade which interventions are most successful. 
Where interventions have been introduced few of them have been evaluated. This may partly be 
because few systematic interventions have been used. 
Council Recommendation on the prudent use of antimicrobial agents in human medicine (2002/77/EC) 
lists a number of areas that have an impact on controlling AMR. Most of the following tentative 
indicators are based on the Council Recommendations. Some are based on experience from different 
countries. These indicators are either structure- or process-related. Outcome indicators are collected 
by dedicated surveillance networks. 
 
 
1. Development of an Intersectoral Coordinating Mechanism (ICM) 
Due to the complexity of the issue there is a need for coordination to make an interventional strategy 
work. There is need for close cooperation from fields such as epidemiology, microbiology clinical 
medicine, infection control, veterinary medicine, pharmacology, behavioural sciences, practitioners 
from different medical specialities as well as government departments and health care providers. 
In the Council Recommendation on the prudent use of antimicrobial agents in human medicine 
(2002/77/EC) and in the WHO Global Strategy for Containment of Antimicrobial Resistance 
(WHO/CDS/CSR/DRS/2001.2) the establishment of a coordinating group is regarded as essential. 
Member States have different administrative organizations. There should be a group on the highest 
administrative level where representatives from regulatory bodies and professionals from the different 
sectors coordinate. 
 
Tentative indicators for 1 
- Structures  
 Multidisciplinary composition 
 Regular meetings 
 Minutes from meetings 
 National strategy plan available 
 Defined governmental mandate 
 Financially supported by government 
- Functions  
 Coordinates analysis of consumption and, plans and supports interventions 
 Proposes national objectives and policies 
 Proposes, plans and supports interventions 
 Provides policymakers, media and public with continues updated and structured data 
 Provides support to local working groups 
 
 
2. Organised multidisciplinary and multisectoral collaboration on local level 
One of the main elements for control strategies is to lower the selective pressure of antibiotics by 
restricting usage to appropriate indications. There is much evidence showing that antibiotics are 
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overused. Prescribers need to be well acquainted with the AMR-problem and with the rational of using 
antibiotics appropriately.  
A non-regulatory intervention that has indicated some influence on prescribing habits are local 
activities where practicing physicians discuss local data on consumption and bacterial resistance 
patterns, supported by epidemiologists, pharmacists and infection control. This proves to be an 
appropriate opportunity to revise local usage patterns, develop local guidelines (based on national 
guidelines) and organise local meetings with prescribers to promote rational use of antibiotics. In 
addition, topical issues can be discussed like problems related to MRSA or Clostridium difficile 027. 
Time for practicing doctors is limited. It is essential that there is a good collaboration with and support 
from the national/regional group to provide background data and help with scientific updates. 
 
Tentative indicators for 2 
General   
- Structures  
 Are there local activities in some places?   
 Are there nationally disseminated local activities?   
 Are activities in hospitals and primary health care coordinated at the local level?  
Primary health care   
- Structures  
 Are there local activities in primary health care?   
 If yes:    
o Mostly multidisciplinary  
o Private practitioners are taking part 
o Have access to local surveillance data on AMR 
o Have access to local antibiotic consumption data 
o Have public funding 
o Meet regularly 
- Functions   
 Primary areas of work are: 
o Infection control 
o Diagnostic practices/habits 
o Analysis of local consumption and resistance data 
o Educational activities 
o Coordination of interventions 
o Provide local guidelines 
o Convene local meetings with prescribers at least yearly 
Hospitals   
- Structures 
 Are there local activities in hospital health care?   
 If yes: 
o Mostly multidisciplinary  
o Have access to local surveillance data on AMR 
o Have access to local antibiotic consumption data 
o Have public funding 
o Meet regularly 
- Functions    
 Primary areas of work are: 
o Infection control 
o Diagnostic practices/habits 
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o Analysis of local consumption and resistance data 
o Educational activities 
o Coordination of interventions 
o Provide local guidelines 
o Convene local meetings with prescribers at least yearly 
 
 
3. Laboratory capacity 
Laboratory capacity is essential for many reasons: 
- To be able to follow trends in antimicrobial resistance; 
- To discover newly emergent resistant strains;  
- To enable prescribers to make informed antibiotic choices. For this there is a need for timely 
feedback to clinicians. 
It is important to characterise isolates that may have clinical importance. This can often not be done in 
all laboratories so a referral system to specialised laboratories should exist. 
All laboratory work should regularly be quality assessed. 
 
Tentative indicators for 3 
General 
- Structures  
 How many diagnostic laboratories are appropriately equipped for microbiological diagnostic work 
(minimum requirement: performance of gram-stain, aerobe culture and antimicrobial susceptibility 
testing). 
 What proportion of microbiological laboratories have at least one specialist clinical/medical 
microbiologist? 
 Is there a formal referral structure to reference laboratories supported by public (alternatively 
through insurance system or equivalent) funding? 
 Does a national external quality assessment scheme exist? 
 Does an accreditation system exist for microbiological laboratories that requires regular QC and 
EQA? 
 
Hospitals 
- Functions  
 What proportion of microbiological laboratories provide preliminary and individual feedback 
(gram stain, rapid tests, culture results) via telephone or clinical rounds to the submitting clinician 
within the first 12 h of receipt of diagnostic specimen?  
 What proportion of microbiological laboratories provide preliminary and individual feedback 
(gram stain, rapid tests, culture results) via telephone or clinical rounds to the submitting clinician 
within the first 24 h of receipt of diagnostic specimen?  
 What proportion of microbiological laboratories provides susceptibility test results to the 
submitting clinician within 48 h of receipt of diagnostic specimen?  
 What proportion of microbiological laboratories provides species identification of blood culture 
isolates to the submitting clinician?  
 Who pays for sent in sample analysis? 
 
Out patients 
- Functions  
 
 
 
 
ECDC country visit to discuss AMR issues COUNTRY VISIT REPORT 
 
 
 
40 
 
 
 
 
 What proportion of general practitioners can submit clinical specimen for microbiological 
investigation to an appropriately equipped microbiological laboratory within 12 hours?   
 What proportion of microbiological laboratories provide preliminary and individual feedback 
(Gram stain, rapid tests, culture results) to the submitting clinician within the first 24 h of receipt of 
diagnostic specimen?  
 What proportion of microbiological laboratories provides susceptibility test results to the 
submitting clinician within 48 h of receipt of diagnostic specimen?  
 Who pays for sent in sample analysis? 
 
 
4. Monitoring of antibiotic resistance 
Resistance patterns should regularly be followed. This should be done with a standardized method. 
The method should regularly be quality assessed. 
To be able to guide prescribers in prudent usage of antibiotics surveys of different clinical conditions 
should be done to define which pathogens and their susceptibility profiles for antibiotics. The 
resistance pattern may vary from area to area so local monitoring may be needed. 
Data should be gathered nationally and internationally to follow long term trends. 
 
Tentative indicators for 4 
 Local, time limited studies have been performed   
 Local continuous, monitoring is done in a few laboratories  
o Are duplicates excluded? 
 National monitoring with standardized methodology on clinically and epidemiologically relevant 
bacterial pathogens is on-going 
 Country wide local monitoring with standardized methodology in communities and hospital unites 
is on-going   
 Data from hospitals and out-patient settings are treated separately 
 Data collection is financially supported by government   
 Regular surveys of resistance patterns for pathogens in population based syndromes are 
performed   
 Regular feedback of resistance patterns to prescribers and local groups is given 
 
 
5. Monitoring of antibiotic usage 
As antibiotic usage is the driving force for emerging resistance it is important to monitor usage. 
Therefore, reliable surveillance systems of antibiotic consumption are essential to complement 
antibiotic resistance data and to develop instruments for assessing effective strategies to foster 
appropriate antibiotic use in all European countries.  
Current antibiotic use surveillance systems are mostly monitoring trends and shifts in usage patterns. 
However, to deepen our understanding of antibiotic prescribing, more detailed information is needed 
on patients’ age and gender, the prescriber, the indication and pathogen. Although prescriber data are 
felt as sensitive, this kind of data can be used for the self assessment. Aggregated data may be used 
for local group discussions. 
 
Tentative indicators for 5 
 Are valid national data on outpatient antibiotic use available? 
 Are valid national (or at least representative sample) data on hospital antibiotic use available? 
 Is collection of data on antibiotic use legally supported? 
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 Is data collection financially supported by the government? 
 Are data available per prescriber/ clinical diagnosis/micro-organism? 
 Is there regular feedback of prescription patterns to prescribers? 
 Are anonymous data fed back to local groups? 
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6. Antibiotic utilisation and treatment guidance 
Antibiotics should be used properly. “Proper use” is a difficult term both in human and veterinary 
medicine. Still there is a need to find some common view on what is “proper”. Guidelines are a way on 
agreeing locally or nationally. 
Antibiotics allow treatment of serious bacterial infections. The largest volume of antibiotics is 
prescribed in ambulatory care. This use is increasingly recognized as the major selective pressure 
driving resistance, which in turn makes them ineffective. Therefore antibiotics should be used 
appropriately, i.e. (no) antibiotics for those who will (not) benefit from the treatment. In addition, 
unnecessary use of antibiotics requires more resources, motivates patients to re-consult and exposes 
them to the additional risk of side effects, whereas under-prescribing could be associated with higher 
risk of complications of untreated infections. 
A “proper” level of usage is difficult to define. The levels are mostly for following trends and shifts in 
usage patterns. With these data related to other data there might be a way of defining a “proper” 
range of usage. One benchmark value on European level cannot be given, because for different 
countries the demographical characteristics and epidemiological situation can influence this indicator. 
Individual countries should position themselves and define their own benchmark. This should be based 
on the epidemiology of infectious diseases and national guidelines. A range of acceptable antibiotic use 
should be defined rather than one threshold value. If the use is outside the limits of the range, more 
detailed assessment is recommended in order to define the action required. For any action planned 
explicit targets should be set. 
Most guidelines define treatment for specific diagnosis. This means that the diagnosis have to be made 
correctly before guidelines are applicable. 
That also means that antibiotic usage must be directed by medical diagnosis and decisions. That is 
why systemic antibiotics are prescription-only medicines in EC. 
 
Tentative indicators for 6 
 Availability of OTC (over-the-counter) antibiotics 
 Availability of national treatment guidelines  
 Availability of locally adapted treatment guidelines  
 Has the compliance to guidelines been assessed? 
 Defined standardised criteria for clinical diagnosis 
 What is the rate of laboratory diagnostics use before deciding on use of antibiotics for sore 
throat (% of patients)? 
 What is the rate of blood cultures before use of antibiotics for perceived bacteraemia with sepsis 
(% of patients)? 
 
 
7. Infection control 
Health care and especially hospitals have historically been a main source of spread of epidemics. This 
has been shown for a wide variety of microbes. This was true with smallpox and early outbreaks of 
Lassa fever. A recent well known example is SARS. Another very well known bacterium that spreads in 
health care settings is MRSA. 
All hospitals have defined procedures and hygienic principles although these may not always be based 
on the latest scientific knowledge. Implementation of guidelines and adherence to procedures is 
another problem. Surveys have shown that adherence to infection control guidelines many times is 
poor. 
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More and more persons with complicated medical conditions are given home-based care. Many of 
them are elderly. Such patients may have indwelling catheters, have a lower immunity and often use 
antibiotics. Infection control guidelines are difficult to follow in a home like setting and many of the 
caring staff has little or no training in infection control. Increasingly MRSA is reported to be a problem 
also in these settings.  
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Tentative indicators for 7  
General 
 Is there a national committee on issues related to infection control? 
Hospitals 
 Alcohol based hand disinfection recommended for non-diarrheal disease 
 Guidelines for hygienic procedures including standardized barrier precautions in >90% of 
hospitals 
 Specific guidelines for MRSA in >90% of hospitals 
 At least one infection control nurse/doctor per hospital 
o Time allocated for infection control? 
 What numbers of hospitals do surveillance of healthcare acquired infections (HAI) regularly in 
ICUs? (% of hospitals) 
 What numbers of hospitals do surveillance of healthcare acquired infections (HAI) regularly in 
surgical wards? (% of hospitals) 
 What numbers of hospitals do surveillance of healthcare acquired infections (HAI) regularly in 
internal medicine wards? (% of hospitals) 
 Are there legal requirements for infection control system in hospitals? 
 Is implementation of infection control practice regularly evaluated? 
 
Health care settings outside hospitals 
 Alcohol based hand disinfection recommended for non-diarrhoeal disease 
 Alcohol based hand disinfection available in >90% of outpatient clinics 
 Alcohol based hand disinfection available in >90% of health care settings for elderly 
 Guidelines for infection control are available for elderly and long term care staff 
 Implementation of infection control practice in elderly and long term care is regularly evaluated 
 
 
8. Educational programmes on AMR 
The understanding of the problem with AMR is the basis for having an impact with interventional 
programmes. This can partially be achieved with educational programmes. Educational programmes 
should be an integrated part of undergraduate studies. All healthcare related professionals need to 
have an understanding of the AMR problem. 
“Education” in the context of AMR is more then just pharmacology of antibiotics or resistance patterns 
in microbes. It encompasses the relation between microbes, antibiotics and the epidemiology of 
resistant strains. It describes the complex interrelation between all aspects brought up in this 
document. 
Regular, repetitive, independent educational material best provided by locally based colleagues in 
discussion groups seems to be one of the better success factors. 
 
Tentative indicators for 8 
 Doctors have in their curriculum AMR as undergraduate course  
 Hospital health care workers have some education on AMR 
 Community health care workers have some education on AMR 
 Specific post graduate courses for doctors in antibiotic resistance are provided 
 Regular educational programmes in antibiotic resistance are provided for health staff 
 It is compulsory for all prescribers to take part regularly in a session on AMR 
 <60% of information on AMR is industry sponsored 
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9. Public information related to AMR 
Many prescribers blame patients for demanding antibiotics irrespective of their condition. This can only 
be changed if the public is well informed about what antibiotics can and can not do. Hence, 
educational activities of the wider public are important. 
 
Tentative indicators for 9 
 No information provided 
 Topic sometimes covered in media 
 Some material for media and/or internet from official sources 
 Occasional national campaigns 
 Repeated, structured national campaigns 
 Regular, structured information provided by professional bodies 
 Public perception assessed 
 
 
10. Marketing related issues 
Economics do have an impact on prescribing habits irrespective of diagnosis or best practice. This 
should be discouraged. 
 
Tentative indicators for 10 
 Independent (not industry supported) drug information is available 
 Ethical guidelines for interrelation between physicians and industry are in place 
 Physician’s prescriptions do not influence on physician’s salary 
 Personal gifts from industry to physicians are illegal 
 
 
 
